COMPASS Pathways (CMPS) stock is in focus after the company reported successful Phase 3 results for its COMP360 therapy and began a rolling FDA New Drug Application, which reduces regulatory uncertainty around its lead program.

The recent clinical success and rolling FDA filing come after a sharp re‑rating in the stock, with a 90 day share price return of 78.56% and a 1 year total shareholder return of 152.43%. However, the 7 day share price return of 12.57% shows some investors are locking in gains after the news driven rally.

If you are interested in how other healthcare related stocks linked to new technology are trading, this is a good moment to look through 40 healthcare AI stocks

After a sharp rerating and strong recent returns, COMPASS Pathways now trades with a very large implied upside to some valuation estimates. The key question is whether this reflects genuine undervaluation or if the market is already pricing in future growth.

Most Popular Narrative: 48% Undervalued

Against the last close at $11.41, the most followed narrative points to a fair value near $21.92, framing COMPASS Pathways as heavily discounted on long term assumptions.

Completion of enrollment in the COMP006 Phase III trial and the plan to use 9 week data from Part A together with 26 week COMP005 data to support a rolling NDA process could shorten the path to potential approval, which would bring revenue forward and may support earlier earnings visibility.

Read the complete narrative. Read the complete narrative.

Curious what justifies that gap between the current price and the implied fair value? The narrative leans on sharp revenue ramp up, margin expansion and a rich future earnings multiple. If you want to see how those ingredients combine into that target, the full narrative sets out each assumption in detail.

Result: Fair Value of $21.92 (UNDERVALUED)

However, this story can change quickly if Phase III data disappoints, or if higher operating spend and potential future capital raises weigh on earnings per share.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Valuation Gap Cuts Both Ways

That 48% implied undervaluation sits awkwardly next to the fact that CMPS trades on a P/B of 4.7x, which is roughly double the US Biotechs industry average of 2.3x, even if it is below the 7.2x peer average. Is the stock cheap on story, or expensive on balance sheet?

To see how that P/B comparison translates into valuation risk and where the market P/B could move toward a fair ratio over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between optimism and caution, it makes sense to move quickly and weigh the data yourself before the story shifts again, starting with the company's 2 key rewards and 4 important warning signs

Looking for more investment ideas?

If you are serious about building a stronger portfolio, this is the moment to widen your search and see what other stocks are offering right now.

• Spot potential value opportunities early by scanning 46 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect them yet.
• Strengthen the core of your holdings by checking solid balance sheet and fundamentals stocks screener (47 results) where companies show resilient financial positions alongside operating discipline.
• Get ahead of the crowd by reviewing the screener containing 20 high quality undiscovered gems before these stories appear on more investors' radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.